Inclusion Criteria:

          -  Histologic confirmed prostatic adenocarcinoma

          -  Non-castrate levels of testosterone (> 150 ng/dL)

          -  High-risk localized prostate cancer, defined by either:

               -  Tumor stage T3 by digital rectal examination, or

               -  Primary tumor Gleason score ≥ 8, or

               -  PSA ≥ 20 ng/mL

          -  Willing to undergo prostatectomy as primary treatment for localized prostate cancer

          -  Adequate hematologic, renal and hepatic function:

               -  WBC > 3000/uL

               -  Platelets > 150,000/uL

               -  Creatinine < 2 mg/dL

               -  Bilirubin < 1.5 x upper limit of normal (ULN)

               -  AST/ALT < 2 x ULN

          -  Karnofsky Performance Status (KPS) ≥ 80%

          -  Able to swallow the study drugs whole as tablets

        Exclusion Criteria:

          -  Pathological finding consistent with small cell, ductal or neuroendocrine carcinoma of
             the prostate

          -  Current or prior hormonal therapy, radiation therapy or chemotherapy for prostate
             cancer

          -  Evidence of metastatic disease (M1) on imaging studies

          -  Other prior malignancy less than or equal to 5 years prior to randomization with the
             exception of squamous or basal cell skin carcinoma

          -  Abnormal cardiac function as manifested by NYHA (New York Heart Association) class III
             or IV heart failure

          -  History of prior cardiac arrhythmia.

          -  Evidence of serious and/or unstable pre-existing medical, psychiatric or other
             condition (including laboratory abnormalities) that could interfere with patient
             safety or provision of informed consent to participate in this study.